BACKGROUND. The live attenuated BPZE1 vaccine candidate induces protection against B. pertussis and prevents nasal colonization in animal models. Here we report on the responses in humans receiving a single intranasal administration of BPZE1.
Introduction
Despite the high vaccination coverage worldwide, pertussis remains a major infectious disease globally in infants and young children (1, 2) . Importantly, it has re-emerged over the past decades, even in industrialized countries with sustained high vaccination rates. The reemergence of pertussis disease accelerated after the replacement of whole cell pertussis vaccines (wPV) by acellular pertussis vaccines (aPV) in the 1990s (3) (4) (5) . Although aPV confers protection to mild and severe disease, the short duration of aPV-induced immunity and inability to prevent nasal colonization and thereby reduce transmission, are proposed major causes of the re-emergence of pertussis (6, 7) . In addition, recent emergence of filamentous hemagglutinin adhesion (FHA)-, pertussis toxin (PT)-, or pertactin (PRN)-negative B. pertussis strains has been reported in countries experiencing epidemics of pertussis as a result of vaccineinduced selection (8) (9) (10) . Evolution of B. pertussis to escape from aPV-induced immunity may therefore be another cause of the resurgence of pertussis (11) .
Effective protection against pertussis likely requires both specific antibodies and T cell responses, in synergy with innate effector cells (12) . Early clinical trials suggested the level of IgG to PT, PRN or fimbriae (FIM) 2/3 as serological correlates of protection in humans, especially after aPV vaccination (13, 14) . However, there is still no consensus on definitive and quantitative immune correlates of protection (15) (16) (17) . The polarization towards a Th1, Th2, or Th17 cellular response appears to significantly influence the quality of protective immunity (7) . In both animal models and humans, immunization with wPV or natural infection induces a dominant Th1 or/and Th17 response, while aPV preferentially induces a Th2 response (12, 18) . Th1 and Th17 cells proved to be more effective at conferring protection compared to Th2 cells (7) which may partly explain the lower quality of aPV-induced immunity.
An intranasal vaccination with a live vaccine would be expected to confer effective mucosal, long-lasting protection, similar to that induced by natural infection (19) . In mice, a single intranasal administration of the live attenuated vaccine candidate BPZE1 induced long-term protection against B. pertussis, mediated by both antibodies and Th1 CD4 + T cells (20, 21) . In baboons, BPZE1 generated full protection against disease and, importantly, against nasopharyngeal colonization upon challenge (22) , while aPV immunization resulted in clearance of the challenge dose from the nasopharynx at the same rate or slower than in unvaccinated naive baboons (23) . The ability of BPZE1 to block colonization offers the unique prospect of blocking circulation of B. pertussis, thereby likely reducing pertussis disease incidence, according to epidemiological modelling (6) .
BPZE1 was recently tested in Sweden in humans (ClinicalTrials.gov, NCT01188512; NCT02453048) and demonstrated good safety in healthy young adults and strong immunogenicity (24) especially using the higher doses tested (Jahnmatz et al., unpublished observations ). In the current study, we characterized the immune responses induced by BPZE1 in human vaccinees more in-depth, with particular emphasis on the Th polarization, antigen specificity and functionality of the antibody responses. The data showed distinct differences in serum antibody breadth, specificity and proportions of subtypes and subclasses between BPZE1-and aPV-induced responses. BPZE1 induced a Th1 polarized response compared to the Th2 response induced by aPV. The BPZE1-induced antibodies further showed superior functionality compared to aPV-induced antibodies with regard to opsonization of B. pertussis, induction of ROS production and bactericidal activity of neutrophils.
Results

Innate immune responses following BPZE1 vaccination
This study was performed in healthy adults receiving intranasal administration of 10 9 colony forming units (CFU) of BPZE1. Using 10 9 CFU, colonization of BPZE1 was detected in 10 out of the 12 vaccinees following administration (Jahnmatz et al, unpublished observations).
Since the early innate immune activation shapes adaptive immunity, we measured the early responses after administration of BPZE1. Leukocytosis is one of the hallmarks of pertussis observed in infants, but rarely seen in adolescents or adults (25) . Due to the mutation in PT, no leukocytosis is observed in naive baboons (22) , so as expected, inoculation of this high dose of BPZE1 in healthy adults did not alter the frequencies of leukocytes in blood (Supplemental Figure 1A ). In addition, no severe adverse events were reported in the BPZE1 vaccinees (Jahnmatz et al, unpublished observations). After vaccination, no changes were seen in the proportions of distinct monocyte subsets, CD11c + myeloid dendritic cells (MDCs) and CD123 + plasmacytoid dendritic cells (PDCs) nor did the expression level of activation or maturation markers on these cells change (Supplemental Figure 1B -C). Since BPZE1 is intranasally administered, direct effects of BPZE1 on cells in the nasopharynx may not be reflected in the blood. We therefore exposed purified monocytes and neutrophils to BPZE1 in vitro and found that BPZE1 induced strong activation of both cell types evidenced by significant upregulation of CD80, CD83, CD86, CD40, CD11b and CCR7 (Supplemental Figure 1D -E). In addition, BPZE1-exposed monocytes, but not neutrophils, produced the pro-inflammatory cytokines IL-1β, IL-6 and TNF (Supplemental Figure 1D -E). This suggests that BPZE1 induces rapid innate immune responses locally but this does not lead to systemic activation of the same cell types.
Early increase of plasmablasts and activated circulating T follicular helper cells
A transient increase in plasmablasts in the blood after infection or vaccination is the result of the germinal center reaction occurring during the development of antibody responses (26) . The magnitude of the transient increase in plasmablasts has been shown to correlate with the magnitude and quality of the humoral response (27, 28) . We found that the level of plasmablasts rapidly increased after BPZE1 immunization and peaked at day 14. As expected, no plasmablast response was observed in the placebo group ( Figure 1A-B ). Circulating T follicular helper (cTfh) cells, proposed as the circulating counterparts of lymphoid Tfh cells (29, 30) , also increased after BPZE1 vaccination. Within the population of CD4 + CXCR5 + cTfh cells, there was a clear expansion of activated PD-1 + ICOS + cells exclusively amongst the Th1type CXCR3 + cTfh (cTfh 1 ) cells at 4-14 days ( Figure 1C -D). It has been shown that the frequency of such activated cTfh 1 cells correlate with the magnitude and quality of antibody responses in HCV-infected individuals or in influenza vaccinated individuals (31) (32) (33) (34) . BPZE1induced PD-1 + ICOS + cTfh 1 cells also showed increased expression of activation markers compared with two other quiescent cTfh 1 cell subsets (PD-1 -ICOSand PD-1 + ICOScells), including CD38, PD-1, CD28, and CD27 ( Figure 1E ). Such activated cTfh 1 subset has been linked to B cell helper function (33) . As expected, the placebo group did not show an increase in activated cTfh 1 . The expansion of plasmablasts and activated cTfh 1 cells therefore demonstrates that an antibody response is generated rapidly following BPZE1 immunization.
Induction of B. pertussis-specific antibodies by BPZE1 vaccination
Since BPZE1 expresses the full spectrum of B. pertussis antigens, we measured the levels of antibodies against the entire bacteria, using the BPZE1 lysate as coating antigens in the ELISA. At 28 days post immunization, BPZE1 vaccinees had significantly increased total IgG and IgA titers against BPZE1 lysates (Figure 2A ). Amongst the 12 immunized individuals, 10 subjects showed ≥1.5-fold induction of BPZE1-specific IgG or IgA, with 6 of them showing a ≥1.5-fold induction of both antibody isotypes (Supplemental Figure 2A) . Interestingly, the two subjects showing no detectable nasopharyngeal colonization after vaccination also mounted robust IgG and IgA titers. BPZE1-specific total IgG titers remained higher than pre-vaccination levels at 6 and 12 months, indicating a durable vaccine response, as also reported in mouse studies (21, 35) . While the IgA waned faster than IgG, they were still elevated at 6 months post vaccination. The total IgG and IgA responses to BPZE1 and the recent clinical isolate BP611-98 were almost identical, showing that the BPZE1-induced antibodies are highly cross-reactive ( Figure 2B -C, Supplemental Figure 2C ). This observation is also supported by the high similarity in protein antigen composition between BPZE1 and BP611-98, as determined by 2D PAGE ( Figure 2D ). In the placebo group the levels of IgG and IgA did not change over time (Supplemental Figure 2B and 2D).
BPZE1 induces a Th1-biased CD4 + T cell response
As mentioned above, in addition to the antibody response, the quality of the T helper cell response is critical in the induction of protection against pertussis (36) . The expansion of activated cTfh 1 cells and not of cTfh 2/17 cells in the BPZE1 vaccinees suggests that BPZE1 primarily induces a Th1-polarized T cell response. Consistently, a dominant Th1-biased CD4 + T cell response was found, as evidenced by a majority of the BPZE1-specific T cells producing TNF-or IFN-γ. No or very limited numbers of Th2 (IL-13) or Th17 (IL-17A) cells were detected ( Figure 2E -G). A proportion of BPZE1-specific CD4 + T cells expressed more than one cytokine indicating polyfunctionality (Supplemental Figure 3 ). The placebo group showed no induction of BPZE1-specific T cells ( Figure 2G ). While animal studies have shown that BPZE1 can also induce Th17 cells apart from Th1 cells, the Th17 responses were restricted to the lung, spleen, or nasal cavity (35, 37) . In addition, in wPV-immunized mice, vaccinespecific Th17 responses were only detectable in the lung or nasal cavity, not in the blood (38) . Therefore, whether BPZE1 in humans is able to elicit a Th17 response in mucosal tissues merits further investigation.
Although early studies indicated that CD8 + T cells are not necessary for protection against pertussis (39, 40) , recent data proposed a role of cytotoxic CD8 + T cells, especially due to the intracellular infection properties of B. pertussis (41, 42) . However, in contrast to the CD4 + T cells, no induction of detectable BPZE1-specific CD8 + T cells were found in the vaccinees (data not shown).
Induction of robust vaccine-specific memory B cell responses by BPZE1
We next evaluated the frequencies of memory B cell populations specific to BPZE1 lysate, a mix of PT, FHA, PRN, and FIM2/3, as well as PT alone. All vaccinees showed a significant IgG memory B cell response to the BPZE1 lysate, as well as to the antigen mix and the majority of individuals also showed PT-specific memory B cell responses ( Figure 3A , 3C). IgA memory B cells were also detected in all vaccinees and recognized BPZE1 lysate and antigen mix, but not PT ( Figure 3B , 3D). The levels of IgG memory B cells correlated with the frequencies of IgA memory B cells for the antigen mix and the lysate ( Figure 3E ). In agreement with the memory B cell data, the serum IgG recognized PT, the antigen mix and the whole lysates, while the serum IgA did not react with PT but did react with the antigen mix and BPZE1 lysates ( Figure 3F ). The lack of PT specific IgA memory B cells may be a consequence of the slow onset of PT expression during the colonization process in the nasal cavity, unlike FHA, PRN and FIM which are fully expressed during initial stages of colonization (43) . In any event, these data suggest that B. pertussis antigens other than PT in BPZE1 do elicit an IgA response.
Differences between the BPZE1 and aPV induced antibody responses
In order to further characterize the Th polarization and antibodies, we benchmarked the responses in the BPZE1 vaccinees to responses induced by aPV immunization ( Figure 4A ). Antibody responses generated 28 days after the 5th vaccination with aPV were compared to the responses induced 28 days after a single immunization with BPZE1. Both groups showed a significant increase in IgG and IgA titers to the BPZE1 lysate, the clinical strain BP611-98, as well as the antigen mix of FHA, PT, PRN, and FIM after immunization ( Figure 4B -D). The total IgG levels were overall higher in the aPV than in the BPZE1 vaccinees, likely due to the repeated immunizations with aPV these individuals have received, which is also reflected in the high baseline levels of antibodies against the antigen mix ( Figure 4D ). In contrast to the high IgG levels, the aPV vaccinees showed lower or similar IgA levels, both prior to and after immunization, compared to the BPZE1 vaccinees ( Figure 4B ). This is in line with the inability of aPV to induce IgA responses in naive mice (37, 44) which means that aPV-induced IgA in humans may primarily be a boost effect of previous subclinical exposure to circulating B. pertussis (45) . In contrast, pre-existing immunity both in terms of IgG and IgA in the BPZE1 vaccinees would exclusively stem from natural exposure. Measurement of the binding strength (avidity and affinity) of the vaccine-induced IgG and IgA after normalizing the antibody levels (OD value=1) showed that the aPV-induced IgG had higher binding strength than BPZE1induced IgG, suggesting that the repeated immunizations resulted in increased binding quality of antibodies ( Figure 4E ). There was no such increase for IgA, again likely due to that aPV is not efficient at inducing IgA responses.
Furthermore, the increase of total IgG in the BPZE1 vaccinees was exclusively contributed by (46, 47) . This is also demonstrated by the ratios of different IgG subclasses ( Figure 4F ). As expected, the levels of different IgG subclasses in the placebo subjects did not change (Supplemental Figure 2 ).
Immunoproteomics profiling of antibody responses induced by BPZE1 and aPV
Apart from the differently polarized responses to BPZE1 vs aPV, other antigens than FHA, PT, PRN and FIM included in aPV may confer better protection (21, 37) . By using a mass spectrometric analysis, we obtained a full proteome map of BPZE1 with 1599 proteins identified (Supplemental Table 2 ). Using gene ontogeny (GO) enrichment analysis, the Figure 4C ). In addition, as a circulating virulent strain, BP611-98 contained FIM3 and DNT, but not FIM2 and adenylate cyclase toxin (ACT). Other immunogenic antigens such as PT, FHA and PRN were present in both BPZE1 and BP611-98.
We combined 2D immunoblotting with LC-MS/MS analysis to in-depth characterize the antigen-binding specificities of the antibodies induced in BPZE1-versus aPV-immunized individuals ( Figure 5A ). Prior to vaccination, the BPZE1 group showed IgG directed to a higher number of antigens than the aPV group ( Figure 5B , left panels), suggesting that while the majority of the subjects in BPZE1 group did not receive pertussis vaccination during childhood, they had pre-existing immunity acquired by natural exposure to B. pertussis, as also detected by ELISA (Figure 2 and 4) . In contrast, the aPV group showed a restricted response of baseline IgG, essentially corresponding to the antigen components of aPV. After vaccination, the IgG response induced by BPZE1 also showed a much broader antigen recognition repertoire than that induced by aPV. In both groups, there was a booster effect of the specific responses detected at baseline. The antigen recognition repertoires of the IgA responses both at baseline and after vaccination were more similar between the BPZE1 and aPV groups than that observed for IgG ( Figure 5C ). This may again be due to priming of IgA responses by natural exposure in both groups.
Identification of novel antigens by LC-MS
The intensities of the spots before and after immunization were quantified using Delta-2D software ( Figure 5D ), measured as the average grey value. In total, 31 protein spots that showed increased intensities or dominant responses following vaccination were selected for protein identification by LC-MS ( Figure 5B -C, Table 1 ). The range of antigens recognized by the antibodies in the respective vaccine groups is shown in Table 1 . BPZE1 induced IgG to multiple antigens, including BrkA that is ubiquitously expressed by B. pertussis mediating complement evasion, GroEL that elicits partial protection against B. pertussis challenge (49), PNPase and LivJ, previously shown to be immunogenic ( Table 2 ). In contrast, aPV-elicited IgG was directed primarily against the vaccine components, especially FHA, PRN, and PT, in line with the ELISA results. The anti-FHA and anti-PRN IgG responses appeared as multiple IgG-binding protein spots ( Figure 5B , Table 1 ), likely due to degradation, deamination or posttranslational modifications (44) .
The specificities of the IgA response induced by BPZE1 also identified a variety of antigens, such as RpsA (spot 03) and GroEL (spot 04) that were able to elicit both IgA and IgG responses, PRN (spot 13) and FHA (spot 18) as well as some novel antigens such as WbpO (spot 17) and
GroES (spot 27). In addition, we observed a "tailed" IgA-binding protein spot at lower molecular weight (spot 28) and although not analyzed in our study, it may represent lipooligosaccharide (44) . aPV-elicited IgA was directed against fewer antigens, such as PRN, BrkA, DnaK and Enolase, the three latter of which are not included in the vaccine. We again speculate that this is the result of natural exposure to B. pertussis or other pathogens exhibiting the same antigens. Given the critical role of IgA in protection against pertussis, we analyzed some of the antigens that solely induced IgA responses (spots labeled with purple circles in Figure 5C ). These antigens were DnaK, PPIase, SODb, DsbA, NusG, PpiB, PT S4, and GroES (Table 1) . Their functions were noted using GO analysis (Supplemental Table 3 ). In addition to PT, FHA, and PRN included in aPV, several other of the antigens we identified ( Table 2) have previously been shown to be immunogenic in either animal or human studies (49) (50) (51) (52) (53) (54) (55) .
BPZE1-induced opsonizing antibodies mediate neutrophil activation and killing
Since neutrophils are major innate effector cells clearing B. pertussis in vaccinated or convalescent mice and not in naïve mice (56, 57) , we assessed whether the antibodies induced by BPZE1 or aPV have different abilities to opsonize bacteria and mediate killing. To test this, we exposed purified human neutrophils to BPZE1 opsonized by 10% of pooled serum from either vaccine group. Reactive oxygen species (ROS), as well as activation (CD11b, CD66, CD63, CD62L) and maturation markers (CD10) were measured. Neutrophils exposed to BPZE1 upregulated CD11b and CD10, and downregulated CD62L, while ROS production was not affected ( Figure 6A ). In contrast, neutrophils exposed to BPZE1 opsonized by baseline serum from the BPZE1 group showed a much higher level of ROS, as well as further increased expression of CD11b, CD66, CD63 and decreased expression of CD62L, likely driven by the opsonizing capacity of the pre-existing antibodies. This effect was further amplified with serum collected 28 days after BPZE1 vaccination. Especially the ROS production was strongly upregulated ( Figure 6A ) and was serum dose-dependent ( Figure 6B ). Increased ROS production over baseline was also found with serum collected 6 and 12 months after vaccination, although at a lower level ( Figure 6C ).
Compared to aPV, BPZE1 has been shown to confer a significantly more efficient bacterial clearance upon challenge (21, 22) . Since the bacterial clearance was largely mediated by phagocytic cells such as neutrophils, we speculated that BPZE1-induced antibodies have better opsonizing capacity to activate neutrophils than aPV-induced antibodies. We therefore performed the same assay by exposing neutrophils to BPZE1 in the presence of vaccineinduced antibodies. In order to compare the activities on an antibody basis we normalized the serum between the groups to obtain equal quantity i.e. 10% and 6% pooled serum of BPZE1 and aPV vaccinees, respectively, based on the mean OD values of the IgG titers ( Figure 4B ).
While both the BPZE1-and the aPV-induced antibodies activated neutrophils, indicated by elevated expression of CD11b and CD66, ROS production was only increased in the presence of BPZE1-induced antibodies ( Figure 6D ). Serum from aPV-immunized subjects failed to induce ROS production at all concentrations tested, up to 15% ( Figure 6E ). Previous studies have shown that ACT released from B. pertussis inhibits ROS in neutrophils, whereas this could be reversed in the presence of ACT-specific antibodies (58) (59) (60) . The BPZE1 vaccinees showed significantly increased titers of IgG and IgA against ACT after vaccination. IgG1 and IgG3 were again the main IgG subclasses induced by BPZE1 ( Figure 6F) . No IgG2 or IgG4 were elicited (data not shown). In contrast, aPV vaccination did not enhance the level of ACTspecific antibodies ( Figure 6F ). This may, at least partly, explain the inability of aPV-induced antibodies to stimulate ROS production.
Antibody-bacteria immune complexes can activate neutrophils through Fc-receptors.
Additionally, complement molecules deposited on the bacterial surface as a result of antibodydependent classical complement activation can activate neutrophils through complement receptors (61) . To investigate whether ROS induction occurred through Fc receptor-or complement-mediated neutrophil activation, we performed the same assay using heat inactivated (HI)-serum from BPZE1 vaccinees in which complement activity is destroyed. We found that HI-serum opsonized BPZE1 also induced ROS production in neutrophils ( Figure   6G ). This indicates that Fc-receptor-mediated opsonophagocytosis plays a dominant role in triggering ROS production by BPZE1-induced serum. Finally, we evaluated neutrophil killing activity following antibody-mediated bacterial opsonization. Enhanced killing by neutrophils was found using serum from either BPZE1 or aPV vaccinees to opsonize the bacteria ( Figure   6H ). This may be due to a combination of both complement-mediated killing and neutrophil killing since the serum alone can kill B. pertussis through the activation of classical complement pathway leading to the formation of membrane attack complex (Supplemental Figure 5 ). In the presence of HI-serum from the BPZE1 vaccinees, neutrophils showed a significantly better killing activity, whereas aPV-induced antibodies did not show this effect, consistent with their inability to stimulate ROS production ( Figure 6H ). Collectively, these data show that BPZE1 is superior over aPV in inducing effective opsonizing antibodies, leading to enhanced bactericidal activity of neutrophils. The induction of anti-ACT antibodies may be one mechanism explaining the better bacterial clearance conferred by BPZE1, as reported in animal studies (21, 22) .
Discussion
Pertussis disease remains an important public health issue given the global rise of pertussis cases during the past decades (2) . There is therefore a critical need for improved pertussis vaccines with high efficacy and low reactogenicity. The live BPZE1 vaccine has been tested in different animal models and demonstrated mucosal and systemic immune responses, longlasting protection, and blocking of nasal colonization upon infection (20, 22) . In human clinical trials, BPZE1 showed excellent safety profiles (24) . In this study, we performed multiple assays to obtain mechanistic insight into the immune responses in humans generated by BPZE1 as compared to aPV. We found that a single intranasal administration of BPZE1 was able to induce well-detectable plasmablasts, activated cTfh1 cells, vaccine-specific CD4 + cells, memory B cells and, ultimately, robust levels of Th1-type antibodies with potent bacterial opsonizing activity. We observed a much wider range of antigen specificities recognized by the antibodies elicited by BPZE1 compared to aPV. Importantly, novel immunogenic antigens in BPZE1 were identified, which may be critical for generation of enhanced protection against
B. pertussis disease and transmission.
With the full spectrum of antigens that BPZE1 expresses, it is not surprising that a wider repertoire of antibodies with multiple specificities can be induced as compared to the aPV. The identification of the immunogenic antigens of BPZE1 to which the antibody responses are directed is of particular importance as the correlates of protection against pertussis have yet to be definitively determined. Antibodies specific to the few aPV antigens are unlikely exclusive for protection since B. pertussis has a complex antigen composition and a large proportion of antigens overlap with other pathogens. In addition, B. pertussis isolates devoid of PRN, FHA, or PT have emerged as a result of bacterial evolution in response to aPV pressure (9, 10). We identified several immunogenic antigens in BPZE1 that have in fact been reported previously (Table 2) . Notably, immunization of neonatal mice with purified GroEL was shown to confer protection against virulent B. pertussis challenge, albeit at a weaker level than that induced by PT (49) . Immunization with recombinant iron superoxide dismutase together with monophosphoryl lipid A (MPLA) induced protective antibody and Th1 cell responses in mice (62) . Vaccination with recombinant BrkA as a single component did not induce protection against pertussis. However, a three-component aPV containing PT, FHA and BrkA was able to generate more effective protection than an aPV containing only PT and FHA in mice (63) . Since innate effector cells such as neutrophils and macrophages play a key role in the clearance of B. pertussis (12) , opsonizing antibodies that bind bacteria to form immune complexes, facilitate uptake and bacterial killing are central. While uptake of bacteria was not evaluated directly in our study, we measured cell activation and ROS production (downstream effects of bacterial uptake). Antibodies from the individuals receiving BPZE1 showed stronger capacity to activate neutrophils and promote ROS production as compared to antibodies from aPV vaccinees, which further led to an enhanced bactericidal activity. This was found to mainly depend on Fc receptor ligation, which is in line with earlier studies (61) . Antibodies from aPV vaccinees still activated neutrophils, but failed to enhance ROS production and promote neutrophil killing functions. It is plausible that this is influenced by the differences in the polarization of IgG subclasses induced by the different vaccines. BPZE1-induced IgG subclasses were only IgG1 and IgG3 that efficiently mediate opsonization, while aPV-induced IgG subclasses contained IgG2 and IgG4 that have no or limited opsonizing function. The mix of subclasses may compete for binding to the bacteria and interfere with uptake and signaling pathways regulating ROS production (67) . Another potential explanation for the failure of aPV serum to stimulate ROS may be related to ACT released by B. pertussis, known to inhibit ROS production of neutrophils through cAMP signaling, which is critical for mediating bacterial evasion from immune responses (68) . Only the BPZE1 vaccinees had induced robust anti-ACT antibodies, which could potentially have resulted in neutralization of ACT and alleviating any inhibition of ROS production. Despite the fact that repeated aPV immunization elicits high antibody titers, these failed to promote ROS production and bacterial killing, which may help explain why B. pertussis can still colonize aPV-immunized individuals. The strong induction of ACT-specific antibodies by BPZE1 is therefore of particular importance. It has been shown that neither wPV nor aPV immunization can elicit anti-ACT antibodies in humans, whereas natural B. pertussis infection does (69) . However, we observed that serum from aPV immunized individuals before the boost immunization already showed strong ability to stimulate ROS production and promote neutrophil bactericidal activity. This is likely due to the high pre-existing level of IgG directed to B. pertussis antigens from natural exposure since IgG-opsonized B. pertussis could enhance phagocytosis by neutrophils, thus promoting the subsequent bacterial killing (61, 70) .
Differently skewed T cell responses also influence the quality of protection differently (36) .
Th1 and Th17 responses, especially when generated within the respiratory tract, contribute to effective protection against pertussis (36, 38) . In mice, BPZE1 has been shown to generate a systemic Th1 response and a local Th17 response (35, 37) . IL-17 and IFN-γ-producing resident memory T (T RM ) cells also appeared at nasal sites upon BPZE1 immunization (37) . We detected a systemic Th1 response induced by BPZE1. While Th17 cells were not detectable systemically, they may perhaps still be elicited and only be present at airway mucosa. This was also indirectly evidenced by the strong induction of vaccine-specific IgA, which is tightly associated with Th17 responses (71) . Whether BPZE1 immunization can re-direct the Th2polarized, less protective immune responses induced by aPV will be essential to investigate in future studies. Initial exposure to aPV has been shown to lock the pertussis-specific immune responses to some degree (18) , but there may be possibilities to shift the pre-formed Th2 signature to Th1/17 favoring pertussis immunity, especially at an early age when immune plasticity still remains. Also, it is not clear to what extent a systemic Th2 signature can suppress a Th1-prone vaccination event such as a colonization by BPZE1 at the local mucosa for 2 to 3 weeks.
In conclusion, this study provides novel findings on increased antibody breadth and bacterial killing functions induced by BPZE1 compared to aPV. BPZE1 is now being tested in Phase II clinical trials in combination with aPV immunization (NCT03541499 and NCT03942406).
Collectively, the data presented here will hopefully also enhance the overall basic understanding of the immunological mechanisms critical for pertussis protection and control.
Materials and Methods
Additional details are available in the Supplemental Materials and Methods
Study subjects, immunization, sample collection
Samples were obtained from two clinical trials registered in ClinicalTrial.gov under NCT02453048 (BPZE1 vaccine study) and NCT00870350 (Tdap vaccine study). Detailed information about the studies is available in ClinicalTrial.gov. In brief, the BPZE1 vaccine study was a randomized, double-blind, placebo-controlled, dose-escalating study. Healthy young adults (18-32 years of age) born in Sweden between 1984 and 1998, with anti-PT and/or PRN serum IgG titers ≤ 20IU/ml, were recruited. Notably, the majority of them were born during the period (year 1979-1996) when pertussis vaccination was suspended in Sweden.
Therefore, any pre-existing antibodies were most likely induced by natural infection with B.
pertussis. We analyzed the responses in all study subjects (n=12) enrolled in the group receiving a single intranasal immunization of the highest dose (10 9 CFU) of BPZE1 in a volume of 0.4 mL per nostril. Samples from the placebo group (n=12 subjects) were also analyzed in some assays as control. Peripheral venous blood was collected in BD Vacutainer CPT tubes at the day prior to vaccination and at days 4, 14 and 28, and months 6 and 12 post vaccination, followed by PBMCs isolation and serum collection. The Tdap vaccine study is a randomized, multi-center study in which the immunogenicity and safety of Tetanus, Diphtheria and Acellular Pertussis Vaccine Booster were evaluated (72, 73) . In part of this clinical trial, adolescents (14-15 years of age) with a vaccination history of three primary immunization of DTaP5 (Connaught HCP4DT) was used for development and the absorbance was read at 450nm (minus 550nm for wavelength correction). Limit of detection is around optical density (OD) value of up to 2.5.
Two-dimensional polyacrylamide gel electrophoresis (2D PAGE)
2D PAGE was performed according to Apostolovic et al (74) . Briefly, bacterial lysates (45µg) were mixed with Destreak Rehydration Buffer and 0.5% IPG Buffer pH 3-11 NL (GE Healthcare), up to a total volume of 125µl. Immobiline DryStrips pH 3-11 NL, 7cm (GE Healthcare) were rehydrated with the samples in a Reswell Tray (GE Healthcare) overnight at 4°C and run on Ettan IPGphor 3 Isoelectric Focusing system according to the protocol: 45min at 300 V (Hold), 1h at 1000 V (Gradient), 1.5h at 5000 V (Gradient), 30min at 5000 V (Hold).
Then, proteins on the strip were reduced with 5 ml of equilibration buffer (6M urea, 75mM
Tris-HCl, pH 8.8, 29.3% glycerol, 2% SDS, 0.002% bromophenol blue) containing 3% DTT (Sigma-Aldrich) for 25 min, followed by alkylation with 5 ml of equilibration buffer containing 3% iodoacetamide (Sigma-Aldrich) for 15 min in dark. Following this, the second dimension of separation was carried on 12.5% hand-cast acrylamide gel in Hoefer Mighty Small II Mini Vertical Electrophoresis System using constant voltage of 180V. Protein spots were visualized by staining the gel with colloidal Coomassie Brilliant Blue solution according to the protocol (75) .
Immunoblotting
After 2D PAGE, proteins were transferred to polyvinylidene difluoride (PVDF, Immobilon P 
Flow cytometric analysis
Cells were collected, washed and then stained with LIVE/DEAD Fixable Blue Dead Cells Stain Kit (ThermoFisher Scientific) prior to incubation with human FcR blocking reagent and antibody cocktails for 20min at RT in the dark. Antibodies used in this study are listed in Supplemental Table 1 . Flow cytometry analysis was carried out on LSRFortessa cell analyzer (BD Biosciences). Data were analyzed using FlowJo V.10.1 (Tree Star).
Statistics
Comparisons between different time points within the BPZE1, aPV and placebo groups were analyzed using two-tailed paired nonparametric Wilcoxon's test. Comparisons between different groups were analyzed using two-tailed unpaired nonparametric Mann Whitney test.
The two-tailed paired student t test was used to analyze data from monocyte/neutrophil stimulation experiments and the neutrophil bactericidal assay. Correlation analysis between two parameters was performed using Pearson's correlation analysis. All statistical analyses were conducted by Prism Version 6.0 software (GraphPad), and the values are presented as mean ± SEM in all figures. A P value less than 0.05 was considered statistically significant.
Study approval
This study was approved by the Swedish Medical Product Agency (MPA) and the Stockholm Local Ethical Committee, and was performed according to the Declaration of Helsinki principles. All subjects gave written informed consent before inclusion in this study. . (B-C) . BPZE1 lysates were separated by 2D PAGE followed by immunoblotting analysis with pooled serum of 12 vaccinees from BPZE1 or aPV group.
Profiles of IgG and IgA responses were evaluated. Two or three independent experiments were performed with similar results. One representative blot is presented. (D). Intensity of the indicated spots was quantified using Delta-2D software. Average grey value is shown. 
